Open house drug discount contracts for the active ingredient Tolvaptan, ATC G04BX21

This tender, announced by AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse (AOK Rhineland-Palatinate/Saarland - The Health Insurance Fund), is an 'Open House' procedure for drug discount contracts. It specifically targets medications containing the active ingredient Tolvaptan, identified by ATC code G04BX21. The 'Open House' format enables interested pharmaceutical companies to submit bids and enter into discount agreements with the health insurance fund over a specified period. The primary goal is to achieve cost savings for the fund through competitive pricing for Tolvaptan-based drugs. Potential bidders are required to review the detailed specifications, including quality, availability, and contractual terms, provided by AOK Rheinland-Pfalz/Saarland. All communication and submissions must be directed to the issuing authority, not the publication platform service.bund.de.

This is a supplies contract in the health and medical services, information and communication technology and finance and banking sectors, with a focus on Pharmaceuticals, Health Financing and Insurance. Located in Germany, Europe, this opportunity is open to firms and consortiums. Proposals must be submitted before February 29, 2028.

Published through service.bund.de (Germany), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.